Related Experiment Video
Updated: May 21, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized
Ali Ghaleiha1, Kadijeh Moghadasian Shahidi, Saeed Afzali
1Department of Psychiatry, Behavioral Disorders & Substance Abuse Center of Hamadan University of Medical Sciences, Hamadan, Iran.
Objective:
By considering the role of adrenergic nervous system in sweat secretion, we postulated that terazosin may be able to improve sweating after taking sertraline, a selective serotonin reuptake inhibitor (SSRI) drug. This study was designed to evaluate the effect of terazosin on sertraline -related sweating.
Methods:
All patients diagnosed with major depressive disorder based on the DSM-IV criteria who were taking sertraline and suffered from excessive sweating were enrolled in the study and randomly allocated into two groups of receiving terazosin (1 mg) or placebo. Sweating severity was classified using Hyperhidrosis Disease Severity Scale. The patients were evaluated regarding the severity of sweating before beginning of the study and 14 days after taking either terazosin or placebo.
Results:
Baseline characteristics including age, sex proportion and weight were not significantly different between the two groups (P > 0.05). At the beginning of the study, 33 (48.5%) and 31 (47%) patients in the terazosin and placebo groups, respectively, suffered from the highest grade of sweating. Fourteen days after treatment with terazosin severity of sweating reduced to the lowest grade in 46 (68%) and two (6%) cases in the terazosin and placebo groups, respectively (P < 0.001).
Conclusions:
Our findings revealed that terazosin may be effective in decreasing sweating severity in patients using sertraline.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Antihypertensive Drugs: Thiazide-Class Diuretics
